| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TRSL.2017.07.004 |
| P698 | PubMed publication ID | 28774752 |
| P50 | author | Sophia Y Lunt | Q57243133 |
| P2093 | author name string | Jamie J Bernard | |
| Martin P Ogrodzinski | |||
| P2860 | cites work | Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. | Q53759105 |
| Diet-induced obesity and mammary tumor development in MMTV-neu female mice. | Q53875708 | ||
| Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. | Q54631030 | ||
| In vivo cancer metabolism is defined by the nutrient microenvironment | Q63346615 | ||
| Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc | Q73819236 | ||
| Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion | Q79518349 | ||
| Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age | Q79521338 | ||
| Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice | Q80341950 | ||
| Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients | Q81682235 | ||
| Effect of obesity on prognosis after early-stage breast cancer | Q82657718 | ||
| Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? | Q82985582 | ||
| Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer | Q86423031 | ||
| AKT-induced tamoxifen resistance is overturned by RRM2 inhibition | Q86991993 | ||
| NMR-based Stable Isotope Resolved Metabolomics in systems biochemistry | Q89418817 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells | Q24561962 | ||
| Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment | Q24611183 | ||
| Brick by brick: metabolism and tumor cell growth | Q24656187 | ||
| Fundamentals of cancer metabolism | Q26744062 | ||
| Cancer Metabolomics and the Human Metabolome Database | Q26767342 | ||
| Research into cancer metabolomics: Towards a clinical metamorphosis | Q26781245 | ||
| Progress in adjuvant chemotherapy for breast cancer: an overview | Q26798078 | ||
| Adipocytes: impact on tumor growth and potential sites for therapeutic intervention | Q26830077 | ||
| Serine and glycine metabolism in cancer | Q26863700 | ||
| Application of metabolomics in drug resistant breast cancer research | Q26866291 | ||
| A roadmap for interpreting (13)C metabolite labeling patterns from cells | Q27003299 | ||
| Glutamine and cancer: cell biology, physiology, and clinical opportunities | Q27011818 | ||
| Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs | Q27303674 | ||
| Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis | Q27671695 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis | Q28074225 | ||
| Metabolomic profiling of hormone-dependent cancers: a bird's eye view | Q28084834 | ||
| Repeated observation of breast tumor subtypes in independent gene expression data sets | Q28131820 | ||
| 5-Fluorouracil: mechanisms of action and clinical strategies | Q28201937 | ||
| Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects | Q28281779 | ||
| Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase | Q28288793 | ||
| Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin | Q28485299 | ||
| Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells | Q28504783 | ||
| Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells | Q28550634 | ||
| Triple-Negative Breast Cancer | Q29391607 | ||
| The Emerging Hallmarks of Cancer Metabolism | Q36468964 | ||
| Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation | Q36477750 | ||
| Obesity as a risk factor for development and poor prognosis of breast cancer | Q36582743 | ||
| EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape | Q36642685 | ||
| Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer | Q36669793 | ||
| Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. | Q36732781 | ||
| Mechanisms of Endocrine Resistance in Breast Cancer | Q36851417 | ||
| The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance | Q36890663 | ||
| Nitric oxide and cancer: a review | Q36893209 | ||
| Heterogeneity of tumor-induced gene expression changes in the human metabolic network | Q36927094 | ||
| Low glucose dependent decrease of apoptosis and induction of autophagy in breast cancer MCF-7 cells | Q36952559 | ||
| Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures | Q36955113 | ||
| Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer. | Q36962829 | ||
| Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer | Q36967938 | ||
| Hypoxia and breast cancer: prognostic and therapeutic implications | Q36980334 | ||
| ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. | Q37023688 | ||
| RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells. | Q37034427 | ||
| Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes | Q37040438 | ||
| MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment | Q37130478 | ||
| The importance of serine metabolism in cancer | Q37145927 | ||
| Clinical applications of metabolomics in oncology: a review | Q37177549 | ||
| Influence of metabolism on epigenetics and disease | Q37177814 | ||
| Minireview: Obesity and breast cancer: the estrogen connection | Q37210759 | ||
| Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer | Q37241740 | ||
| mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer | Q37295289 | ||
| Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells | Q37299640 | ||
| Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors | Q37401534 | ||
| Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes | Q37474410 | ||
| The angiogenic switch in carcinogenesis | Q37501499 | ||
| The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug | Q37501673 | ||
| Biological determinants of endocrine resistance in breast cancer | Q37585095 | ||
| Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration | Q37586501 | ||
| Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target | Q37596851 | ||
| Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials | Q29547513 | ||
| The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth | Q29547680 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Aerobic glycolysis: meeting the metabolic requirements of cell proliferation | Q29615178 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Metformin and reduced risk of cancer in diabetic patients | Q29616275 | ||
| Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction | Q29616653 | ||
| c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism | Q29617213 | ||
| Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| Regulation of angiogenesis by hypoxia: role of the HIF system | Q29619187 | ||
| MYC on the path to cancer | Q29619979 | ||
| US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status | Q30665329 | ||
| The molecular portraits of breast tumors are conserved across microarray platforms | Q33241398 | ||
| Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
| Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling | Q33710602 | ||
| Chemotherapy-induced anemia in adults: incidence and treatment | Q33746941 | ||
| Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute | Q33751139 | ||
| Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast cancer cells | Q33817324 | ||
| Associations between energy balance and body mass index and risk of breast carcinoma in women from diverse racial and ethnic backgrounds in the U.S. | Q33855674 | ||
| PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). | Q33883406 | ||
| Pegylated arginase I: a potential therapeutic approach in T-ALL | Q33944287 | ||
| Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors | Q33967878 | ||
| Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia | Q33996661 | ||
| Glutamine addiction: a new therapeutic target in cancer | Q34050094 | ||
| Physiological consequences of ectopic agouti gene expression: the yellow obese mouse syndrome | Q34051659 | ||
| Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth | Q34147708 | ||
| Functional genomics reveal that the serine synthesis pathway is essential in breast cancer | Q34200610 | ||
| Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis | Q34205126 | ||
| Glycolysis, glutaminolysis and cell proliferation | Q34268269 | ||
| Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. | Q34272156 | ||
| Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance | Q34346725 | ||
| Oncometabolites: linking altered metabolism with cancer | Q34368256 | ||
| Adiposity and sex hormones in postmenopausal breast cancer survivors | Q34374845 | ||
| TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists | Q34391710 | ||
| Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. | Q34392877 | ||
| The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 | ||
| Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study | Q39605778 | ||
| Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors | Q39690774 | ||
| Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis | Q39721070 | ||
| Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway | Q40185356 | ||
| Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes | Q40341736 | ||
| Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database. | Q40553911 | ||
| Endogenous hormones and breast cancer risk | Q40862184 | ||
| The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer | Q41605356 | ||
| The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. | Q41839639 | ||
| Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation | Q42442143 | ||
| Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues | Q42451893 | ||
| High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation | Q42461741 | ||
| Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis | Q42461745 | ||
| Metabolic phenotypes in triple-negative breast cancer | Q43639032 | ||
| Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status | Q43785983 | ||
| Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells | Q43969327 | ||
| Breast cancer incidence rates in U.S. women are no longer declining | Q44617798 | ||
| Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations | Q46575022 | ||
| Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism | Q46743426 | ||
| Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts | Q46879124 | ||
| [18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition | Q47235205 | ||
| Adiposity, adult weight change, and postmenopausal breast cancer risk | Q47264748 | ||
| Dual effects of weight and weight gain on breast cancer risk | Q47300501 | ||
| Body size and risk of breast cancer | Q47308309 | ||
| High incidence of HER-2 positivity in inflammatory breast cancer | Q47955100 | ||
| Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. | Q50573578 | ||
| PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis. | Q51298888 | ||
| Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism. | Q51616949 | ||
| Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. | Q53058972 | ||
| Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. | Q53076367 | ||
| Estrogen receptors: role in breast cancer. | Q53595317 | ||
| Interplay of choline metabolites and genes in patient-derived breast cancer xenografts | Q37689772 | ||
| Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. | Q37690915 | ||
| Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells | Q37692621 | ||
| Pubertal and adult windows of susceptibility to a high animal fat diet in Trp53-null mammary tumorigenesis | Q37696322 | ||
| Inflammatory breast cancer: the disease, the biology, the treatment | Q37801500 | ||
| Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways | Q37861928 | ||
| Insulin resistance of amino acid and protein metabolism in type 2 diabetes | Q37865137 | ||
| Targeting cancer metabolism: a therapeutic window opens | Q37924094 | ||
| Adipocyte is a non-trivial, dynamic partner of breast cancer cells | Q37939013 | ||
| The impact of obesity on breast cancer: a retrospective review. | Q37997377 | ||
| Cancer cell metabolism: one hallmark, many faces. | Q38046274 | ||
| Cholesterol metabolism and resistance to tamoxifen. | Q38051937 | ||
| Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond | Q38063400 | ||
| Inflammatory breast cancer: an overview | Q38280412 | ||
| Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery. | Q38311249 | ||
| Mitochondria as biosynthetic factories for cancer proliferation. | Q38332527 | ||
| Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development | Q38360743 | ||
| Organ-Specific Cancer Metabolism and Its Potential for Therapy. | Q38441997 | ||
| Metabolic control of signalling pathways and metabolic auto-regulation | Q38442728 | ||
| 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes | Q38446353 | ||
| Obesity and Cancer: The Oil that Feeds the Flame | Q38697729 | ||
| Natural fatty acid synthase inhibitors as potent therapeutic agents for cancers: A review | Q38728759 | ||
| Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development | Q38768309 | ||
| Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions | Q38792334 | ||
| Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells | Q38797549 | ||
| Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics. | Q38822368 | ||
| Cancer treatment and survivorship statistics, 2016. | Q38859236 | ||
| Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer | Q39024340 | ||
| Understanding the Intersections between Metabolism and Cancer Biology | Q39130440 | ||
| Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. | Q39149779 | ||
| Glutaminolysis: A Hallmark of Cancer Metabolism. | Q39182095 | ||
| An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer. | Q39247409 | ||
| Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer | Q39405012 | ||
| Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine | Q39412274 | ||
| Hypoxia-Inducible Factors: Master Regulators of Cancer Progression | Q39456881 | ||
| Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab | Q39558712 | ||
| Trends in Obesity Among Adults in the United States, 2005 to 2014. | Q34530004 | ||
| Molecular links between obesity and breast cancer | Q34530905 | ||
| HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers | Q34586591 | ||
| Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells | Q34613543 | ||
| Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34655579 | ||
| Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells | Q34752692 | ||
| A history of cancer chemotherapy | Q34869530 | ||
| Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation | Q34898927 | ||
| Metabolic characterization of triple negative breast cancer | Q34967995 | ||
| MYC and Breast Cancer | Q34972381 | ||
| The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma | Q35013613 | ||
| Hormone responsive human breast cancer in long-term tissue culture: effect of insulin | Q35043073 | ||
| Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts | Q35124597 | ||
| 18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers | Q35141499 | ||
| Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management | Q35187357 | ||
| cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions. | Q35291859 | ||
| Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP | Q35567021 | ||
| Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy | Q35654022 | ||
| MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism | Q35669189 | ||
| Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells | Q35679199 | ||
| The role of estrogen in the initiation of breast cancer | Q35698844 | ||
| Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. | Q35836097 | ||
| Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications | Q35938054 | ||
| Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype | Q35989767 | ||
| Forecasting individual breast cancer risk using plasma metabolomics and biocontours | Q36024150 | ||
| Trastuzumab: updated mechanisms of action and resistance in breast cancer | Q36036437 | ||
| Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis | Q36090325 | ||
| c-Myc transactivation of LDH-A: implications for tumor metabolism and growth | Q36238451 | ||
| Akt-dependent transformation: there is more to growth than just surviving | Q36313173 | ||
| Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer | Q36371490 | ||
| Estrogen modulates metabolic pathway adaptation to available glucose in breast cancer cells | Q36454569 | ||
| Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice. | Q36465239 | ||
| P304 | page(s) | 105-122 | |
| P577 | publication date | 2017-07-15 | |
| P1433 | published in | Translational Research | Q15761127 |
| P1476 | title | Deciphering metabolic rewiring in breast cancer subtypes | |
| P478 | volume | 189 |
| Q57193351 | FOXF2 differentially regulates expression of metabolic genes in non-cancerous and cancerous breast epithelial cells |
| Q92823311 | Imaging breast cancer using hyperpolarized carbon-13 MRI |
| Q91974693 | Metabolic reprogramming in triple-negative breast cancer |
| Q65001698 | Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. |
| Q91740817 | Mitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity |
| Q55509868 | The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer? |
Search more.